- Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
- Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
- Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
- Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
- Anaptys Named a BioSpace 2024 Best Places to Work Winner
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
- Anaptys Announces Participation in November Investor Conferences
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 580.00 |
Average volume | -- |
---|---|
Shares outstanding | 27.32m |
Free float | 26.80m |
P/E (TTM) | -- |
Market cap | 638.16m USD |
EPS (TTM) | -6.13 USD |
Data delayed at least 20 minutes, as of Oct 27 2020 11:30 BST.
More ▼